• MAPK10 Phosphorylation of KRT16 Suppresses NSCLC Metastasis

  2026-07-05

  This study identifies MAPK10 as a kinase that suppresses non-small cell lung cancer (NSCLC) metastasis by phosphorylating keratin 16 (KRT16), leading to its ubiquitination and degradation. The findings highlight a novel MAPK10/KRT16/RNF213 axis as a potential therapeutic and prognostic target for NSCLC.

• Pericyte-Targeted Prodrug Strategy to Overcome VDA Resistanc

  2026-07-04

  This study pioneers a pericyte-targeting prodrug approach to circumvent resistance in vascular disrupting agent (VDA) therapy, a longstanding barrier to solid tumor eradication. By engineering an FAPα-activated prodrug, the authors demonstrate selective disruption of VDA-resistant peripheral tumor vasculature and complete regression in preclinical models, offering a compelling new direction for tumor microenvironment modulation.

• Structural Insights into Tiamulin-Ribosome Interactions and

  2026-07-03

  This study elucidates the molecular basis of how Tiamulin and related pleuromutilin antibiotics interact with the bacterial ribosomal peptidyl transferase center. It highlights resistance mechanisms involving ribosomal protein L3 and 23S rRNA mutations, offering a foundation for rational antibiotic design and improved veterinary therapies.

• Talabostat Mesylate: Mechanistic Insights and Strategic Valu

  2026-07-03

  Explore how Talabostat mesylate (PT-100) advances translational cancer research through dual DPP4 and FAP inhibition, impacting tumor microenvironment, T-cell immunity, and hematopoiesis. This thought-leadership article weaves mechanistic clarity with protocol guidance and strategic positioning, contextualizing recent discoveries on inflammasome regulation and drawing actionable lessons for researchers targeting the tumor stroma.

• Carrier-Free Triterpene Prodrugs for Targeted OSCC Therapy

  2026-07-02

  This study introduces a carrier-free, self-assembled prodrug platform using triterpenes and ROS-responsive linkers for targeted oral squamous cell carcinoma (OSCC) chemotherapy. The approach achieves synergistic drug release and apoptosis with reduced systemic toxicity, providing a promising direction for future chemotherapeutic design.

• CRISPRi Targeting Fabp4 in Adipocytes Mitigates Obesity and

  2026-07-02

  This study introduces a targeted CRISPR interference (CRISPRi) system to silence Fabp4 specifically in white adipocytes, demonstrating significant reductions in obesity, inflammation, hepatic steatosis, and insulin resistance in vivo. The findings advance gene therapy strategies for metabolic disease by addressing tissue-specific delivery challenges and highlight new directions for precision interventions in liver disease research.

• PF-562271 HCl: Precision FAK/Pyk2 Inhibitor for Tumor Resear

  2026-07-01

  PF-562271 HCl empowers cancer researchers to dissect and modulate focal adhesion kinase signaling with nanomolar accuracy. This guide offers hands-on protocols, troubleshooting insights, and bridges novel circRNA findings to practical assay design—making APExBIO’s inhibitor a cornerstone for advanced tumor biology studies.

• Cardioprotection by SGLT2 Inhibitors: Is It a Class or Drug

  2026-07-01

  This study investigates whether cardioprotective effects observed with SGLT2 inhibitors are consistent across different drugs or attributable to individual agents. Using a non-diabetic mouse model of myocardial ischemia/reperfusion injury, the research demonstrates that empagliflozin and dapagliflozin reduce infarct size at standard doses, whereas ertugliflozin only does so at higher dosing. The findings highlight crucial mechanistic differences within the SGLT2 inhibitor class, informing future translational research.

• FGFR3 Inhibition with NVP-BGJ398 Ameliorates SLC26A2 Chondro

  2026-06-30

  This study uncovers that pharmacological inhibition of FGFR3 signaling, particularly via NVP-BGJ398 phosphate, significantly ameliorates skeletal defects in mouse models of SLC26A2-related chondrodysplasia. These findings provide rigorous genetic and pharmacological evidence for targeting the FGFR pathway in rare skeletal dysplasias, informing future translational and therapeutic directions.

• GSK343: Advancing EZH2 Inhibitor Assays for Epigenetic Cance

  2026-06-30

  Explore how GSK343, a potent EZH2 inhibitor, transforms cancer epigenetics research by enabling precise histone H3K27 trimethylation inhibition. This article uniquely bridges chromatin regulation, TERT expression, and practical assay optimization.

• Distinct Cell Death Pathways in ALL Cells After Microtubule

  2026-06-29

  This study reveals that primary acute lymphoblastic leukemia (ALL) cells undergo phase-specific cell death upon microtubule depolymerization, with apoptosis in M phase and a caspase-independent pathway in G1. These findings refine our understanding of microtubule targeting agent (MTA) mechanisms and have implications for optimizing cancer therapies targeting both mitotic and interphase cancer cell populations.

• Dorsomorphin 2HCl: AMPK Inhibitor Workflows in Metabolic Res

  2026-06-29

  Dorsomorphin 2HCl, a benchmark AMPK inhibitor, is central to dissecting metabolic and bone morphogenetic pathways with high specificity in preclinical models. This guide details optimized workflows, troubleshooting tips, and key translational insights—bridging protocol nuance with real-world use-cases in iron homeostasis and hepatic lipid research.

• Elobixibat Hydrate: Mechanistic Insights and Protocol Advanc

  2026-06-28

  Explore the in-depth mechanism of Elobixibat hydrate, a leading ileal bile acid transporter inhibitor, and learn how its unique pharmacology can refine research protocols in metabolic and gastrointestinal studies. Uncover scientific distinctions and practical assay guidance beyond standard product reviews.

• 1-myristoylglycerophosphocholine: Applied Lipid Signaling in

  2026-06-27

  1-myristoylglycerophosphocholine (14:0 Lyso-PC) is redefining how researchers interrogate lipid signaling in smooth muscle and pulmonary fibrosis models. This guide demystifies experimental design, troubleshooting, and advanced applications, translating new mechanistic insights into actionable protocols for lipid pathway analysis.

• Pterostilbene Enhances Mitochondrial Quality to Delay Dermal

  2026-06-26

  Zhou et al. (2025) demonstrate that pterostilbene mitigates senescence in human dermal fibroblasts by improving mitochondrial quality, principally through enhanced mitophagy. These findings clarify mechanisms underlying dermal aging and suggest mitochondrial quality control as a promising intervention target.

461 records 13/31 page Previous Next First page 上5页 1112131415 下5页 Last page